Novel respirable rifampicin curcumin loaded nanoparticles against Mycobacterium tuberculosis infection

ALARCON LILIANA; RIEMER CAROLINA; PELLEGRINI JOAQUIN; GARCIA VERONICA; TATEOSIAN NANCY; MARTINENA, CAMILA; MARTIN CANDELA; RIEDEL JENNIFER; AMIANO NICOLAS; CHIAPPETA, DIEGO; PALMAS LUCIA; DONNOLI LUCIA; MORELLI PAULLA; BERNABEU EZEQUIEL; MORETTON, MARCELA

Congreso; Reunión Anual de Sociedades de Biociencia; 2020

SAIC SAI SAFIS

Rifampicin( is one of the most powerful and effective first line drug employed in the treatment of Mycobacterium tuberculosis Mtb infection With the worldwide emergenceof highly drug resistant tuberculosis ( novel agents that have direct antimycobacterial effects or that enhance host immunity are urgently needed It was described theimmunomodulatory anti TB effects of Curcumin ( a potent anti oxidant and apoptosis inducer compound We develop novel RIF CUR nanoparticles (RIF CUR NP) withimproved drug aqueous solubility and stability for inhalator administration Then, we analyzed by confocal microscopy the in vitro uptake of CUR NP 40 µg/ml) in humanmacrophages (derived from PBMCs) at different time points 1 h, 18 h, 24 h and 48 h) We found a higher drug cellular uptake levels ( area) for Mtb antigen stimulated cells0 2525±0 04 than unstimulated control 0 0707±0 02 over 18 hours (ANOVA test, p< 0 05 Finally, in vitro studies showed the higher microbicidal effect (CFU counts) of the RIFCUR NP 1 µg/ml 1 25 µg/ml) versus RIF NP 1 µg/ml) in THP 1 cells infected with MtbH 37 Rv at 48 hours and 4 days (ANOVA test, p< 0 05 In summary, the RIF CUR nanocarrierprovides a new simple nanotechnological alternative for its potential application in respirable TB therapy